Radio Episodes
4/12/2022
C. diff. Spores and More
Our guests from Seres Therapeutics shared the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). Listen Now
6/29/2021
C. diff. Spores and More
Our guests from Seres Therapeutics shared the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). Listen Now
2/16/2021
C. diff. Spores and More
Join us with our guests from Seres Therapeutics as they discuss the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. Listen Now
9/22/2020
C. diff. Spores and More
Join us with our guests from Seres Therapeutics as they discuss the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. Listen Now
8/18/2020
C. diff. Spores and More
Join us with our guests from Seres Therapeutics as they discuss the latest news
on SER-109 and positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. Listen Now
11/7/2017
C. diff. Spores and More
Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Listen Now
10/24/2017
C. diff. Spores and More
Join us with our guest Barbara McGovern, MD. Since 2012 Dr. McGovern has been working within the pharmaceutical arena and currently is head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Listen Now